A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.
Young Saing KimJun Ho JiSung Yong OhSuee LeeSeok Jae HuhJi Hyun LeeKi-Hoon SongChoon Hee SonMee Sook RohGyeong Won LeeJeeyun LeeSeung Tae KimChan Kyu KimJoung Soon JangIn Gyu HwangHee Kyung AhnLee Chun ParkSo Yeon OhSeong-Geun KimSang-Cheol LeeDo-Hyoung LimSoon Il LeeJung Hun KangPublished in: The oncologist (2019)
EGF ointment is effective for managing ERSEs. It can also improve patients' QoL compared with placebo. Clinical trial identification number. NCT02284139 IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer who are treated with epidermal growth factor (EGF) receptor (EGFR) inhibitors may experience dermatologic reactions to their treatment. This study investigated the benefit of an EGF ointment in the treatment of these adverse events and observed the ointment to be effective in managing EGFR inhibitor-related skin adverse events.
Keyphrases
- growth factor
- epidermal growth factor receptor
- tyrosine kinase
- clinical trial
- small cell lung cancer
- advanced non small cell lung cancer
- wound healing
- end stage renal disease
- newly diagnosed
- healthcare
- primary care
- ejection fraction
- chronic kidney disease
- soft tissue
- double blind
- prognostic factors
- peritoneal dialysis
- endothelial cells
- oxidative stress
- study protocol